Trial
NCT02681523
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Imperial College London
Collaborators
—
Condition
Breast Cancer
Intervention
Eribulin
Why stopped
Slow patient recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19